[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-439927-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-439927-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-new-era-in-chronic-spontaneous-urticaria-fda-approval-of-the-oral-btk-inhibitor-remibrutinib","A new era in chronic spontaneous urticaria - FDA approval of the oral BTK inhibitor remibrutinib","","On 30 September 2025, the U.S. Food and Drug Administration approved Rhapsido® (remibrutinib) as the first targeted oral therapy for chronic spontaneous urticaria (CSU) in adults symptomatic despite H1-antihistamines. CSU is a relapsing inflammatory disorder driven by mast cell and basophil activation via FcεRI and BTK signaling, causing histamine and cytokine release. Remibrutinib covalently inhibits BTK to interrupt the upstream inflammatory cascade. Phase III REMIX-1 and REMIX-2 trials showed rapid, significant, and sustained improvements in UAS7, ISS7, and HSS7 versus placebo, with about one-third achieving complete resolution by week 12. Safety was acceptable with mostly mild adverse events and no routine laboratory monitoring, supporting a paradigm shift toward immune-targeted oral treatment.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-new-era-in-chronic-spontaneous-urticaria-fda-approval-of-the-oral-btk-inhibitor-remibrutinib/439927/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-new-era-in-chronic-spontaneous-urticaria-fda-approval-of-the-oral-btk-inhibitor-remibrutinib/439927.png","ImageObject",300,407,{"name":42,"@type":43},"McGucket","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-29",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What did the FDA approve for chronic spontaneous urticaria on 30 September 2025?","Question",{"text":63,"@type":64},"The FDA approved Rhapsido® (remibrutinib) as the first targeted oral therapy for chronic spontaneous urticaria in adults who remain symptomatic despite H1-antihistamine treatment.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does remibrutinib work in CSU according to the article?",{"text":68,"@type":64},"Remibrutinib is a selective covalent BTK inhibitor that interrupts inflammatory signaling in mast cells and basophils, reducing histamine and cytokine release upstream of symptom generation.",{"name":70,"@type":61,"acceptedAnswer":71},"What outcomes did the Phase III REMIX-1 and REMIX-2 trials show?",{"text":72,"@type":64},"The trials reported rapid, significant, and sustained improvements in Urticaria Activity Score (UAS7), Itch Severity Score (ISS7), and Hives Severity Score (HSS7) versus placebo, with symptom relief beginning as early as Week 2; about one-third achieved complete resolution by week 12.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},439927,1790768073,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":26,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":97,"preview_page_count":4},1236954412713,"https://us-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Letter to the Editor  \nA new era in chronic spontaneous urticaria: FDA approval of the oral BTK inhibitor remibrutinib  \nMahnoor Jan, MBBSa , Khola Qazi, MBBSb , Aliya Noor, MBBSc , Mawra Naveed, MBBSa , Maliha Khalid, MBBSb , Aminath Waafira, MBBSd ,*  \nAbstract  \nOn 30 September 2025, the U.S. Food and Drug Administration (FDA) approved Rhapsido® (remibrutinib) as the first targeted oral therapy for chronic spontaneous urticaria (CSU) in adults who remain symptomatic despite H1-antihistamine treatment. This approval marks a major advancement in CSU management, offering a convenient, precision-based alternative to injectable biologics such as omalizumab. CSU is a chronic, relapsing inflammatory skin disorder characterized by recurrent wheals and angioedema, often accompanied by sleep disturbance, emotional distress, and reduced quality of life. The pathophysiology involves abnormal activation of mast cells and basophils through the IgE receptor (FcεRI) and downstream Bruton’s tyrosine kinase (BTK) signaling, leading to histamine and cytokine release. Remibrutinib, a potent and selective covalent BTK inhibitor, interrupts this inflammatory cascade at its source, thereby providing upstream control of disease activity. FDA approval was based on Phase III REMIX-1 and REMIX-2 trials, which demonstrated rapid, significant, and sustained improvements in Urticaria Activity Score (UAS7), Itch Severity Score (ISS7), and Hives Severity Score (HSS7) compared with placebo. Approximately one-third of patients achieved complete symptom resolution by week 12, and the drug showed an acceptable safety profile with mostly mild adverse events and no need for routine laboratory monitoring. The introduction of remibrutinib represents a paradigm shift in CSU therapy, transitioning from symptomatic relief toward immune-targeted, patient-friendly oral treatment. Future studies should evaluate longterm safety, real-world efficacy, and cost-effectiveness to fully define its role in personalized CSU management.  \nKeywords: BTK inhibitor, chronic spontaneous urticaria, mast cells, remibrutinib, targeted therapy  \nDear Editor,  \nThis letter to the editor adheres to the TITAN guideline on the need for transparency in AI use in healthcare [1] . On 30 September 2025, the U.S. Food and Drug Administration (FDA) approved Rhapsido® (remibrutinib) as an oral therapy for chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite treatment with H1-antihistamines. This approval represents the first targeted oral therapy with a novel mechanism of action for CSU, marking a paradigm shift in treatment by moving beyond symptom control toward upstream immune pathway modulation[2] .  \naDepartment of Medicine, Shaikh Khalifa Bin Zayed Al Nahyan Medical and Dental College, Lahore, Pakistan, bDepartment of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan, cDepartment of Medicine, King Edward Medical University, Lahore, Pakistan and dDepartment of Medicine, The Maldives National University, Malé, Maldives  \nSponsorships or competing interests that may be relevant to content are disclosed at the end of this article.  \n*Corresponding author. Address: Department of Medicine, School of Medicine, The Maldives National University, Rahdhebai Hingunc, Malé 20026, Maldives.  \nTel.: +[960 919-5504. E-mail: wafiagany@gmail.com](960 919-5504. E-mail: wafiagany@gmail.com) (A. Waafira).  \nCopyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nAnnals of Medicine & Surgery (2026) 88:974–975  \nReceived 26 October 2025; Accepted 1 November 2025  \nPublished online 24 November 2025  \n[http://dx.doi.org/10.1097/MS9.0000000000004298](http://dx.doi.org/10.1097/MS9.0000000000004298)  \nCSU is a distressing dermatologic d","cbCaihc0uppruxdy","https://ap.wps.com/l/cbCaihc0uppruxdy","pdf",187017,"English","# Abstract\n# Letter to the Editor\n## FDA approval and mechanism of action\n## CSU background and unmet need\n## Clinical trial evidence and outcomes\n## Safety and future directions","[{\"question\":\"What did the FDA approve for chronic spontaneous urticaria on 30 September 2025?\",\"answer\":\"The FDA approved Rhapsido® (remibrutinib) as the first targeted oral therapy for chronic spontaneous urticaria in adults who remain symptomatic despite H1-antihistamine treatment.\"},{\"question\":\"How does remibrutinib work in CSU according to the article?\",\"answer\":\"Remibrutinib is a selective covalent BTK inhibitor that interrupts inflammatory signaling in mast cells and basophils, reducing histamine and cytokine release upstream of symptom generation.\"},{\"question\":\"What outcomes did the Phase III REMIX-1 and REMIX-2 trials show?\",\"answer\":\"The trials reported rapid, significant, and sustained improvements in Urticaria Activity Score (UAS7), Itch Severity Score (ISS7), and Hives Severity Score (HSS7) versus placebo, with symptom relief beginning as early as Week 2; about one-third achieved complete resolution by week 12.\"}]","A new era in chronic spontaneous urticaria - FDA approval of the oral BTK inhibitor remibrutinib | PDF",1790690540]